Moreover, intrinsic or accumulated drug resistance rapidly makes these agents ineffective and severely limits the therapeutic window33. Elevated NQO1 overexpression in a variety of solid tumors, including pancreatic cancer, has emerged as an effective tumor-selective target3–6. Here, NQO1 is linked to pancreatic neoplasm.